Zidesamtinib shows 94% response rate in TKI-naive advanced ROS1-positive lung cancer
New results from the global Phase I/II ARROS-1 trial indicate clinically meaningful activity with the investigational drug zidesamtinib in patients ...
Tag: TKI-naive
POPULAR NEWS
-
Holographic ultrasound opens the blood-brain barrier to deliver stroke therapies
-
Zidesamtinib shows 94% response rate in TKI-naive advanced ROS1-positive lung cancer
-
Natural Farming Shows Promise for Climate-Resilient Soils, but Evidence Gaps Remain
-
Pulsed Drip Irrigation and Moderate Nitrogen Boost Photosynthesis in Sugarcane